首页 > 市场调查报告书 > 製药

处方药

市场调查报告书

商品编码

1956581

塔西美替胺市场报告：趋势、预测和竞争分析（至2031年）

Tasimelteon Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2026年02月25日 | 出版商:

Lucintel | 英文 211 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

受医院和诊所市场机会的推动，全球他西美酮市场预计将成为一个充满前景的市场。预计2025年至2031年，全球他西美酮市场将以12.1%的复合年增长率成长。这个市场的主要驱动因素包括睡眠障碍盛行率的上升、对非成瘾性治疗方法需求的增长以及人们对昼夜节律紊乱认识的提高。

Lucintel预测，在预测期内，各类学名药的成长率将高于其他产品类型。
在各类申请类别中，医院预计将呈现更高的成长率。
从区域来看，预计亚太地区在预测期内将达到最高的成长率。

塔西美替胺市场的新趋势

受睡眠障碍治疗进展和人们对昼夜节律紊乱日益增长的认识的推动，他西美替胺市场正在快速发展。不断深入的研究和监管核准的扩大为创新治疗方法创造了新的机会。市场相关人员正致力于个人化医疗、技术整合和扩大适应症，以满足不断增长的患者需求。这些发展正在重塑竞争格局，影响定价策略，并改善病患疗效。对于希望掌握市场成长潜力并有效满足未被满足的需求的相关人员，了解这些新兴趋势至关重要。

昼夜节律紊乱盛行率上升：昼夜节律紊乱（包括非24小时睡眠-觉醒节律紊乱）盛行率的不断上升，推动了对tasimelteon的需求。人口老化、轮班工作和生活方式的改变等因素都促成了这一增长。为了应对这一趋势，製药公司正在加大研发投入，以改善现有疗法并开发新的製剂，从而扩大市场规模并提高患者的用药可及性。
监管核准与适应症拓展：近期，包括美国食品药物管理局 (FDA) 在内的多家机构核准他西美坦用于治疗非24小时视觉障碍者，增强了市场信心。此外，正在进行的探索其在其他睡眠相关疾病中疗效的临床试验有望拓展其适应症。这些监管里程碑将加速药物上市速度，扩大健保覆盖范围，并鼓励投资，从而拓宽治疗范围，提高患者获得他西美坦的途径。
科技整合与个人化医疗：睡眠追踪设备和行动医疗应用程式等数位健康工具的整合正在改变治疗效果的监测方式。基于遗传和生活方式因素的个人化给药方案正在兴起，以改善治疗结果。这一趋势使得治疗更具针对性，减少了副作用，并提高了患者的依从性。这使得tasimelteon成为睡眠障碍管理这个更广泛框架下的个人化解决方案。
提高认知度和诊断率：宣传活动的加强和诊断技术的进步正在提高昼夜节律紊乱的检出率。早期诊断有助于及时启动治疗，例如使用他西美酮，从而改善患者的生活品质。这一趋势促使医疗专业人员更加重视睡眠障碍，推动积极主动的治疗方法，并透过提高处方率扩大市场。
竞争格局与市场整合：市场正面临来自非专利生产商和开发替代疗法的新兴参与企业的日益激烈的竞争。为了增强产品系列，企业之间普遍进行策略联盟和併购。这种整合有助于提升研发能力、降低成本并加速创新，最终使患者获得更多样化、更经济实惠的治疗选择。

总而言之，这些新兴趋势正在透过扩大适应症、提高治疗个人化和改善可及性，显着地重塑他西美酮市场，这将促进创新、推动市场成长并改善患者预后，为未来几年市场的持续发展奠定基础。

塔西美替胺市场近期趋势

受睡眠障碍治疗进展和人们对昼夜节律紊乱日益增长的认识的推动，他西美酮市场正经历快速增长。药物製剂的创新和适应症的拓展为製药公司创造了新的机会，而监管部门的核准和策略合作则进一步加速了市场扩张。全球对有效睡眠解决方案日益增长的需求促使相关人员专注于研发，以满足不同患者的需求。这些趋势正在创造一个充满活力的市场环境，为未来的成长和市场主导地位奠定了坚实的基础。

睡眠障碍的上升趋势：昼夜节律紊乱（包括<24小时睡眠-觉醒节律紊乱）的发病率不断上升，推动了对tasimelteon的需求，使其成为重要的治疗选择。这一趋势刺激了製药业的投资和研发，促进了市场扩张。医护人员和病患对睡眠健康的日益重视也进一步推动了产品的普及。随着人们对睡眠障碍的意识提高，越来越多的患者群体能够获得标靶治疗，这将推动市场稳步成长。
监管核准与适应症拓展：近期，包括美国食品药物管理局 (FDA) 在内的监管机构核准了tasimelteon，证实了其疗效并使其应用范围得以扩大。新增适应症，例如时差反应和轮班工作紊乱，正在开闢新的收入来源。这些核准有助于新药进入市场，并改善新兴地区的药物可近性。简化的核准流程和积极的临床试验结果鼓励企业加强研发投入，这有望促成更多适应症的核准，并推动市场持续成长。
药物製剂创新：药物传递系统的进步，包括缓释製剂，正在提高他西美酮的疗效和病人依从性。这些创新减少了给药频率，改善了治疗效果，使治疗更具吸引力。改良的製剂还能最大限度地减少副作用，提高患者的接受度。随着製药公司致力于改进製剂，市场将受益于更高的依从性和更广泛的患者群体，最终提升销售额和市场份额。
策略联盟与伙伴关係：与製药公司和研究机构的合作正在加速tasimelteon的研发和商业化。这些伙伴关係有助于我们获得新技术和开拓新市场，从而增强产品平臺。策略联盟也支持临床试验和监管流程，缩短产品上市时间。这些合作促进创新，丰富产品系列，并巩固我们的市场地位，确保我们在不断发展的睡眠障碍治疗领域保持持续成长和竞争优势。
加大研发投入和市场拓展：不断增加的研发投入正推动他西美酮新製剂和给药方法的发现。各公司也积极开拓包括新兴经济体在内的尚未开发的市场，以满足未被满足的医疗需求。这种对创新和扩张的重视有望提高市场渗透率和收入来源。研发投入的加强将带来更有效的治疗方法，进一步巩固他西美酮在睡眠障碍治疗领域的地位，并支持其长期市场成长。

近期这些进展正透过扩大适应症、改善製剂和加强策略合作，显着影响他西美酮市场。监管部门的核准和研发投入的增加正在推动创新和市场渗透。随着全球对睡眠障碍的认识不断提高，该市场有望持续成长，为相关人员带来新的机会。总而言之，这些进展有望创造一个竞争激烈且充满创新的环境，以满足不同患者的需求并改善治疗效果。

The future of the global tasimelteon market looks promising with opportunities in the hospital and clinic markets. The global tasimelteon market is expected to grow with a CAGR of 12.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of sleep disorders, the rising demand for non-habit forming treatments, and the growing awareness of circadian rhythm disruptions.

Lucintel forecasts that, within the type category, generic drug is expected to witness higher growth over the forecast period.
Within the application category, hospital is expected to witness higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Tasimelteon Market

The tasimelteon market is experiencing rapid evolution driven by advancements in sleep disorder treatments and increasing awareness of circadian rhythm disorders. As research progresses and regulatory approvals expand, new opportunities emerge for innovative therapies. Market players are focusing on personalized medicine, technological integration, and expanding indications to meet growing patient needs. These developments are reshaping the competitive landscape, influencing pricing strategies, and enhancing patient outcomes. Understanding these emerging trends is crucial for stakeholders aiming to capitalize on the markets growth potential and address unmet medical needs effectively.

Growing Prevalence of Circadian Rhythm Disorders: The increasing incidence of conditions like Non-24-Hour Sleep-Wake Disorder (Non-24) and other circadian rhythm disruptions is driving demand for Tasimelteon. Factors such as aging populations, shift work, and lifestyle changes contribute to this rise. This trend prompts pharmaceutical companies to invest in research and development to improve existing therapies and develop new formulations, ultimately expanding market size and accessibility for affected patients.
Regulatory Approvals and Expanded Indications: Recent approvals by agencies like the FDA for Tasimelteon in treating Non-24 in blind individuals have boosted market confidence. Additionally, ongoing clinical trials exploring its efficacy for other sleep-related disorders are likely to lead to expanded indications. These regulatory milestones facilitate market entry, increase insurance coverage, and encourage investment, thereby broadening the therapeutic scope and increasing patient access to Tasimelteon.
Technological Integration and Personalized Medicine: The integration of digital health tools, such as sleep tracking devices and mobile health apps, is transforming how treatment efficacy is monitored. Personalized dosing regimens based on genetic and lifestyle factors are emerging, enhancing treatment outcomes. This trend allows for more targeted therapies, reduces adverse effects, and improves patient adherence, positioning Tasimelteon as a tailored solution within the broader sleep disorder management landscape.
Rising Awareness and Diagnosis Rates: Increased awareness campaigns and improved diagnostic techniques are leading to higher detection rates of circadian rhythm disorders. Early diagnosis enables timely intervention with therapies like Tasimelteon, improving patients quality of life. This trend also encourages healthcare providers to consider sleep disorders more seriously, fostering a proactive approach to treatment and expanding the market through higher prescription rates.
Competitive Landscape and Market Consolidation: The market is witnessing increased competition from generic manufacturers and new entrants developing alternative therapies. Strategic collaborations, mergers, and acquisitions are common as companies aim to strengthen their portfolios. This consolidation enhances research capabilities, reduces costs, and accelerates innovation, ultimately benefiting patients through more diverse treatment options and potentially lower prices.

In summary, these emerging trends are significantly reshaping the tasimelteon market by expanding its scope, improving treatment personalization, and increasing accessibility. They foster innovation, drive market growth, and enhance patient outcomes, positioning the market for sustained development in the coming years.

Recent Developments in the Tasimelteon Market

The tasimelteon market is experiencing rapid growth driven by advancements in sleep disorder treatments and increased awareness of circadian rhythm disorders. Innovations in drug formulations and expanding indications are opening new opportunities for pharmaceutical companies. Regulatory approvals and strategic collaborations are further accelerating market expansion. As the demand for effective sleep solutions rises globally, stakeholders are focusing on research and development to meet diverse patient needs. These developments are shaping a dynamic landscape with significant potential for future growth and market dominance.

Growing Prevalence of Sleep Disorders: Increasing cases of non-24-hour sleep-wake disorder and other circadian rhythm disruptions are driving demand for Tasimelteon, positioning it as a vital treatment option. This trend encourages pharmaceutical investments and research, expanding market reach. The rising awareness among healthcare providers and patients about sleep health further boosts product adoption. As sleep disorders become more recognized, the market is expected to grow steadily, with new patient populations gaining access to targeted therapies.
Regulatory Approvals and Expanded Indications: Recent approvals by regulatory agencies like the FDA have validated Tasimelteon's efficacy, enabling broader use. Expanded indications for conditions such as jet lag disorder and shift work disorder are opening new revenue streams. These approvals facilitate market entry in emerging regions, increasing accessibility. The streamlined approval process and positive clinical trial outcomes are encouraging companies to invest in further research, which will likely lead to additional indications and sustained market growth.
Innovation in Drug Formulations: Advances in drug delivery systems, including sustained-release formulations, are enhancing Tasimelteon's effectiveness and patient compliance. These innovations reduce dosing frequency and improve therapeutic outcomes, making the treatment more appealing. Improved formulations also minimize side effects, increasing patient acceptance. As pharmaceutical companies focus on formulation improvements, the market will benefit from increased adherence and expanded patient base, ultimately boosting sales and market share.
Strategic Collaborations and Partnerships: Collaborations between pharmaceutical firms and research institutions are accelerating Tasimelteon development and commercialization. These partnerships facilitate access to new technologies and markets, enhancing product pipelines. Strategic alliances also support clinical trials and regulatory processes, reducing time-to-market. Such collaborations foster innovation, diversify product portfolios, and strengthen market positioning, ensuring sustained growth and competitive advantage in the evolving sleep disorder treatment landscape.
Increasing Investment in R&D and Market Expansion: Rising investments in research and development are driving the discovery of new formulations and delivery methods for Tasimelteon. Companies are also expanding into untapped markets, including emerging economies, to capitalize on unmet needs. This focus on innovation and expansion is expected to increase market penetration and revenue streams. Enhanced R&D efforts will likely lead to improved therapies, further solidifying Tasimelteon's role in sleep disorder management and supporting long-term market growth.

Conclusion (80 Words) - These recent developments are significantly impacting the tasimelteon market by expanding its applications, improving formulations, and fostering strategic collaborations. Regulatory approvals and increased R&D investments are driving innovation and market penetration. As awareness of sleep disorders grows globally, the market is poised for sustained growth, offering new opportunities for stakeholders. Overall, these advancements are shaping a competitive, innovative landscape that promises to meet diverse patient needs and enhance treatment outcomes.

Strategic Growth Opportunities in the Tasimelteon Market

The tasimelteon market is poised for significant expansion driven by the increasing prevalence of sleep disorders, aging populations, and advancements in sleep disorder treatments. Rising awareness and regulatory approvals are opening new avenues for product development and market penetration. Strategic collaborations and technological innovations further enhance growth prospects. As healthcare providers seek effective solutions for circadian rhythm disorders, the market is expected to witness robust demand, creating opportunities for manufacturers, researchers, and stakeholders to capitalize on emerging needs.

Expanding Use in Treatment of Non-24-Hour Sleep-Wake Disorder: Tasimelteon's approval for Non-24-Hour Sleep-Wake Disorder, primarily affecting blind individuals, presents a substantial growth opportunity. Increasing diagnosis rates and awareness are driving demand. The drug's efficacy in regulating circadian rhythms positions it as a preferred treatment, encouraging pharmaceutical companies to invest in marketing and distribution. Ongoing research may extend its application to other sleep-related conditions, further broadening market scope and revenue potential.
Growing Demand Due to Rising Prevalence of Sleep Disorders: The global rise in sleep disorders, including insomnia and circadian rhythm disruptions, fuels the need for targeted therapies like Tasimelteon. Aging populations and lifestyle factors contribute to this trend. Healthcare providers are increasingly adopting pharmacological solutions, boosting sales. Market players are focusing on expanding access through clinical trials and regulatory approvals in new regions, which will enhance product availability and stimulate overall market growth.
Strategic Collaborations and Licensing Agreements to Accelerate Market Penetration: Companies are forming strategic alliances to enhance Tasimelteon's market reach. Licensing agreements facilitate entry into emerging markets with regulatory support, reducing time-to-market. Collaborations with research institutions foster innovation and new formulation development. These partnerships enable resource sharing, risk mitigation, and increased marketing efforts, ultimately accelerating adoption rates and expanding the customer base, thereby strengthening the market position of key players.
Technological Innovations and Formulation Improvements to Enhance Efficacy: Advances in drug delivery systems and formulation techniques are improving Tasimelteon's bioavailability and patient compliance. Novel delivery methods, such as sustained-release formulations, can extend therapeutic effects and reduce dosing frequency. These innovations increase treatment adherence and satisfaction, leading to higher market acceptance. Continuous R&D investments are expected to yield more effective, safer, and user-friendly products, further driving market growth and competitive advantage.
Increasing Regulatory Approvals and Market Expansion in Emerging Economies: Regulatory approvals in new regions are opening untapped markets for Tasimelteon. Governments are recognizing sleep disorders as a healthcare priority, facilitating faster approval processes. Market expansion strategies include local manufacturing and partnerships with regional distributors. This growth in emerging economies offers significant revenue opportunities, diversifies market risk, and supports global market expansion, ultimately contributing to the overall growth trajectory of the tasimelteon market.

The overall impact of these opportunities is a robust growth trajectory for the tasimelteon market, driven by technological, regulatory, and demographic factors. Strategic initiatives and expanding applications will enhance market competitiveness and accessibility. As awareness and demand increase, stakeholders are positioned to benefit from sustained growth, innovation, and improved patient outcomes, shaping a promising future for the industry.

Tasimelteon Market Driver and Challenges

The tasimelteon market is influenced by a variety of technological, economic, and regulatory factors that shape its growth trajectory. Advances in pharmaceutical research and development have led to innovative formulations and targeted therapies, boosting market potential. Economic factors such as increasing healthcare expenditure and rising prevalence of sleep disorders further propel demand. Regulatory approvals and supportive government policies facilitate market entry and expansion. However, challenges like stringent regulatory requirements, high R&D costs, and patent expirations pose significant hurdles. Understanding these drivers and challenges is essential for stakeholders to navigate the complex landscape and capitalize on emerging opportunities effectively.

The factors responsible for driving the tasimelteon market include:-

Technological Advancements: The development of novel drug delivery systems and formulations enhances drug efficacy and patient compliance, fostering market growth. Continuous innovation in pharmacology and clinical research accelerates the approval of new indications, expanding the market scope. Additionally, advancements in diagnostic tools improve patient identification, ensuring targeted therapy and better outcomes, which in turn increases demand for Tasimelteon.
Rising Prevalence of Sleep Disorders: Increasing incidences of conditions like Non-24-Hour Sleep-Wake Disorder and other circadian rhythm sleep disorders, especially among blind and elderly populations, drive the need for effective treatments. Growing awareness and diagnosis rates contribute to higher prescription rates, supporting market expansion. The aging population worldwide further amplifies this demand, as sleep disorders are more prevalent among older adults.
Regulatory Approvals and Supportive Policies: Approval from regulatory bodies such as the FDA and EMA for Tasimelteon as a treatment for specific sleep disorders boosts market confidence. Supportive policies promoting research and development in sleep medicine facilitate faster drug approvals and market entry. Additionally, reimbursement policies and insurance coverage improve patient access, encouraging widespread adoption.
Increasing Healthcare Expenditure: Rising healthcare spending globally enables better access to advanced therapies like Tasimelteon. Investments in sleep disorder management programs and clinical research foster innovation and market growth. The expanding healthcare infrastructure, especially in emerging economies, provides new opportunities for market players to introduce and promote Tasimelteon.

The challenges in the tasimelteon market are:

Stringent Regulatory Requirements: Navigating complex approval processes and meeting safety and efficacy standards can delay product launches and increase costs. Regulatory agencies often require extensive clinical data, which prolongs development timelines and impacts profitability. Variability in regulatory frameworks across regions adds to the complexity, requiring strategic planning for global market entry.
High R&D Costs and Time: Developing new formulations and conducting comprehensive clinical trials demand significant financial investment and time. These costs can be prohibitive for smaller companies and may hinder innovation. The lengthy development cycle also exposes companies to market risks, such as changing regulatory landscapes and competitive pressures.
Patent Expirations and Generic Competition: The expiration of patents for key formulations opens the market to generic competitors, leading to price erosion and reduced profit margins. This intensifies competition and pressures companies to innovate continuously. Maintaining market share becomes challenging as generic versions offer similar efficacy at lower prices, impacting revenue streams.

In summary, the tasimelteon market is driven by technological innovations, increasing sleep disorder prevalence, regulatory support, and rising healthcare expenditure. However, it faces challenges from regulatory complexities, high R&D costs, and patent expirations. These factors collectively influence market dynamics, requiring stakeholders to strategize effectively. While growth opportunities are substantial, addressing the challenges is crucial for sustained success. Overall, the markets future depends on balancing innovation with regulatory and competitive considerations to meet the growing demand for sleep disorder treatments.

List of Tasimelteon Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tasimelteon companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tasimelteon companies profiled in this report include-

Vanda Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Lupin Limited
Zydus Lifesciences Limited
Dr. Reddys Laboratories Ltd.
Aurobindo Pharma Limited

Tasimelteon Market by Segment

The study includes a forecast for the global tasimelteon market by type, distribution channel, application, end use, and region.

Tasimelteon Market by Type [Value from 2019 to 2031]:

Original Drug
Generic Drug

Tasimelteon Market by Distribution Channel [Value from 2019 to 2031]:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Tasimelteon Market by Application [Value from 2019 to 2031]:

Hospital
Clinic
Others

Tasimelteon Market by End Use [Value from 2019 to 2031]:

Adult Population
Geriatric Population
Shift Workers
Others

Tasimelteon Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Tasimelteon Market

The tasimelteon market has experienced notable developments driven by increasing awareness of circadian rhythm disorders and advancements in pharmaceutical research. As a treatment for conditions like Non-24-Hour Sleep-Wake Disorder, especially among blind individuals, the markets growth is influenced by regulatory approvals, technological innovations, and expanding clinical applications. Countries are adopting new strategies to enhance drug accessibility and improve patient outcomes, reflecting a global focus on sleep health. These developments are shaping the future landscape of the tasimelteon market, with key players investing in research and expanding their geographic reach to meet rising demand.

United States: The US market has seen significant growth due to FDA approval of Tasimelteon for Non-24-Hour Sleep-Wake Disorder. Increased awareness and insurance coverage have improved patient access. Major pharmaceutical companies are investing in clinical trials to explore additional indications, and technological advancements in drug delivery systems are enhancing efficacy. The government's focus on sleep health research further supports market expansion, with a rising number of clinical studies and partnerships driving innovation.
China: China's tasimelteon market is emerging, supported by increasing prevalence of sleep disorders and rising healthcare expenditure. Local pharmaceutical companies are investing in research collaborations to develop generic versions and improve drug accessibility. Regulatory pathways are becoming more streamlined, encouraging market entry. Additionally, growing awareness about sleep health and government initiatives to improve healthcare infrastructure are contributing to market growth, although the market remains relatively nascent compared to Western countries.
Germany: In Germany, the market benefits from a well-established healthcare system and high awareness of sleep disorders. Regulatory approval processes are efficient, facilitating quicker market access for new formulations and indications. The country's focus on personalized medicine and technological integration in healthcare is fostering innovative approaches to Tasimelteon therapy. Collaborations between academic institutions and pharmaceutical companies are advancing research, and reimbursement policies are favorable, supporting broader patient access.
India: The Indian tasimelteon market is in its early stages but shows promising growth potential due to increasing awareness of sleep disorders and rising healthcare investments. Local manufacturers are exploring cost-effective manufacturing options to make the drug more affordable. Government initiatives aimed at improving healthcare infrastructure and increasing sleep disorder diagnosis rates are driving demand. Additionally, the expanding pharmaceutical sector and rising prevalence of sleep-related issues among the population are expected to propel market development.
Japan: Japan's market is characterized by high healthcare standards and a focus on sleep health management. Regulatory approval processes are rigorous but efficient, enabling timely access to Tasimelteon. The aging population and increasing prevalence of sleep disorders are key drivers. Japan is also investing in research to explore new therapeutic uses of Tasimelteon, with collaborations between biotech firms and academic institutions. Reimbursement policies and a strong emphasis on innovative treatments support the market's steady growth and adoption.

Features of the Global Tasimelteon Market

Market Size Estimates: Tasimelteon market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Tasimelteon market size by various segments, such as by type, distribution channel, application, end use, and region in terms of value ($B).
Regional Analysis: Tasimelteon market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, applications, end uses, and regions for the tasimelteon market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tasimelteon market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the tasimelteon market by type (original drug and generic drug), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (hospital, clinic, and others), end use (adult population, geriatric population, shift workers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 6 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Tasimelteon Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Original Drug : Trends and Forecast (2019-2031)
4.4 Generic Drug : Trends and Forecast (2019-2031)

5. Global Tasimelteon Market by Distribution Channel

5.1 Overview
5.2 Attractiveness Analysis by Distribution Channel
5.3 Hospital Pharmacies : Trends and Forecast (2019-2031)
5.4 Retail Pharmacies : Trends and Forecast (2019-2031)
5.5 Online Pharmacies : Trends and Forecast (2019-2031)

6. Global Tasimelteon Market by Application

6.1 Overview
6.2 Attractiveness Analysis by Application
6.3 Hospital : Trends and Forecast (2019-2031)
6.4 Clinic : Trends and Forecast (2019-2031)
6.5 Others : Trends and Forecast (2019-2031)

7. Global Tasimelteon Market by End Use

7.1 Overview
7.2 Attractiveness Analysis by End Use
7.3 Adult Population : Trends and Forecast (2019-2031)
7.4 Geriatric Population : Trends and Forecast (2019-2031)
7.5 Shift Workers : Trends and Forecast (2019-2031)
7.6 Others : Trends and Forecast (2019-2031)

8. Regional Analysis

8.1 Overview
8.2 Global Tasimelteon Market by Region

9. North American Tasimelteon Market

9.1 Overview
9.2 North American Tasimelteon Market by Type
9.3 North American Tasimelteon Market by Application
9.4 The United States Tasimelteon Market
9.5 Canadian Tasimelteon Market
9.6 Mexican Tasimelteon Market

10. European Tasimelteon Market

10.1 Overview
10.2 European Tasimelteon Market by Type
10.3 European Tasimelteon Market by Application
10.4 German Tasimelteon Market
10.5 French Tasimelteon Market
10.6 Italian Tasimelteon Market
10.7 Spanish Tasimelteon Market
10.8 The United Kingdom Tasimelteon Market

11. APAC Tasimelteon Market

11.1 Overview
11.2 APAC Tasimelteon Market by Type
11.3 APAC Tasimelteon Market by Application
11.4 Chinese Tasimelteon Market
11.5 Indian Tasimelteon Market
11.6 Japanese Tasimelteon Market
11.7 South Korean Tasimelteon Market
11.8 Indonesian Tasimelteon Market

12. ROW Tasimelteon Market

12.1 Overview
12.2 ROW Tasimelteon Market by Type
12.3 ROW Tasimelteon Market by Application
12.4 Middle Eastern Tasimelteon Market
12.5 South American Tasimelteon Market
12.6 African Tasimelteon Market

13. Competitor Analysis

13.1 Product Portfolio Analysis
13.2 Operational Integration
13.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

14.1 Value Chain Analysis
14.2 Growth Opportunity Analysis
- 14.2.1 Growth Opportunity by Type
- 14.2.2 Growth Opportunity by Distribution Channel
- 14.2.3 Growth Opportunity by Application
- 14.2.4 Growth Opportunity by End Use
14.3 Emerging Trends in the Global Tasimelteon Market
14.4 Strategic Analysis
- 14.4.1 New Product Development
- 14.4.2 Certification and Licensing
- 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

15.1 Competitive Analysis Overview
15.2 Vanda Pharmaceuticals Inc.
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.3 Teva Pharmaceutical Industries Ltd.
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.4 Sun Pharmaceutical Industries Ltd.
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.5 Lupin Limited
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.6 Zydus Lifesciences Limited
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.7 Dr. Reddy's Laboratories Ltd.
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.8 Aurobindo Pharma Limited
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

16. Appendix

16.1 List of Figures
16.2 List of Tables
16.3 Research Methodology
16.4 Disclaimer
16.5 Copyright
16.6 Abbreviations and Technical Units
16.7 About Us
16.8 Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

塔西美替胺市场报告：趋势、预测和竞争分析（至2031年）

Tasimelteon Market Report: Trends, Forecast and Competitive Analysis to 2031

目录

第一章执行摘要

第二章 市场概览

第三章：市场趋势与预测分析

4. 全球他西美替胺市场（按类型划分）

5. 全球他西美替胺市场按分销管道划分

6. 全球他西美酮市场按应用领域划分

7. 全球他西美酮市场依最终用途划分

第八章 区域分析

第九章 北美塔西美替胺市场

第十章 欧洲塔西美替胺市场

第十一章：亚太地区泰西美替胺市场

第十二章 其他地区的塔西梅尔特昂市场

第十三章 竞争分析

第十四章：机会与策略分析

第十五章 价值链主要企业的公司概况

第十六章附录